Immunosuppression News and Research

RSS

Immunosuppression involves an act that reduces the activation or efficacy of the immune system. Some portions of the immune system itself have immuno-suppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions.

Synta announces results from ganetespib Phase 2b trial on NSCLC

Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).

29 Sep 2012

Shingles becoming more common in Australia

The herpes zoster virus, which causes shingles, is becoming more common as the population ages. In Australia the number of cases has doubled between 2000 and 2010. Hospital emergency departments report a 2–6% increase in cases per year.

28 Sep 2012

Astellas seeks FDA approval for tacrolimus NDA for prophylaxis of organ rejection

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for tacrolimus extended release capsules for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients.

24 Sep 2012

Even partially matched bone marrow transplants can eliminate sickle cell disease in some patients

In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms and the need for a lifetime of pain medications and blood transfusions.

24 Sep 2012

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially-matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms, and the need for a lifetime of pain medications and blood transfusions. The researchers say the use of such marrow could potentially help make bone marrow transplants accessible to a majority of sickle cell patients who need them.

21 Sep 2012

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

21 Sep 2012

Friendly bacteria: do we really need to eat probiotic yogurts?

According to the World Health Organization (WHO) probiotics are “live microorganisms which when administered in adequate amounts confer a health benefit on the host”.

19 Sep 2012

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

Soligenix, Inc., a development stage biopharmaceutical company, announced today that the National Cancer Institute has awarded Soligenix a Small Business Innovation Research grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestation of chronic Graft-versus-Host disease.

5 Sep 2012

HemoSep device significantly reduces need for blood transfusions during major surgeries

A pioneering surgical blood salvage technology developed at the University of Strathclyde, Glasgow, is set to transform the way major surgery is carried out by reducing blood loss in patients.

21 Aug 2012

Diabetes Research Institute to receive JDRF-HCT grant for islet encapsulation study

JDRF, in collaboration with The Leona M. and Harry B. Helmsley Charitable Trust (HCT), announced today that it has finalized a grant in the area of islet cell encapsulation to Dr. Camillo Ricordi, M.D. and a team of investigators at the Diabetes Research Institute (DRI), based at the University of Miami (FL).

17 Aug 2012

FDA requests Biovest to conduct second Phase III trial of BV301 for NHL

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that it conducted a formal clinical guidance meeting with the U.S. FDA to determine the most expeditious U.S. registration pathway for BiovaxID, its personalized cancer vaccine for the consolidation treatment of follicular non-Hodgkin's lymphoma.

15 Aug 2012

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Pfizer Inc. announced that the Phase 3 INTORACT trial (B1771006), evaluating the combination of bevacizumab plus TORISEL (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-α-2a) in the first-line treatment of patients with advanced renal cell carcinoma (RCC) across risk groups, did not meet its primary endpoint of superiority in extending progression free survival (PFS) in the study population.

12 Aug 2012

Schizophrenia may be linked to immune function

New Australian research shows that the brains of people with schizophrenia may be under attack by the immune system, providing the strongest evidence to date of a link between immune function and schizophrenia.

7 Aug 2012

Rituximab also benefits patients with kidney disorder

A drug commonly used to treat immune disorders such as lymphoma and arthritis also benefits patients with an immune disorder of the kidneys that can lead to kidney failure, according to a study appearing in an upcoming issue of new study in the Journal of the American Society of Nephrology (JASN).

28 Jul 2012

Sirolimus has anti-skin cancer effect in kidney transplant patients

Switching from calcineurin inhibitors to a sirolimus-containing immunosuppression regimen may help reduce the incidence of secondary skin cancer after kidney transplantation, suggests research published in TheNew England Journal of Medicine.

27 Jul 2012

Pneumococcal revaccination needed in kidney transplant patients

Kidney transplant patients vaccinated against Streptococcus pneumoniae appear to be protected against pneumococcal infection for at least 15 months, research shows.

23 Jul 2012

Thrombopoietin mimetic offers aplastic anemia hope

Eltrombopag significantly improves blood counts in some patients with refractory severe aplastic anemia, suggests research published in The New England Journal of Medicine.

11 Jul 2012

UCLA Heart Transplant Program performs 2,000th heart transplant surgery

The UCLA Heart Transplant Program performed its 2,000th heart transplant surgery earlier this month, becoming the first program in the western United States and only the second in the world to achieve this remarkable milestone.

28 Jun 2012

Scientists reverse diabetes in mice using stem cells

University of British Columbia scientists, in collaboration with an industry partner, have successfully reversed diabetes in mice using stem cells, paving the way for a breakthrough treatment for a disease that affects nearly one in four Canadians.

28 Jun 2012

REG3A molecule may lead to new treatments for psoriasis, wound-healing

Psoriasis is an autoimmune disorder in which skin cells proliferate out of control. For some hard-to-heal wounds, the problem is just the opposite: Restorative skin cells don't grow well or fast enough. In a paper published in the June 21, 2012 issue of Immunity, researchers at the University of California, San Diego School of Medicine describe a molecule that may lead to new treatments for both problems.

22 Jun 2012

Immunosuppression News and Research

Further Reading

Synta announces results from ganetespib Phase 2b trial on NSCLC

Shingles becoming more common in Australia

Astellas seeks FDA approval for tacrolimus NDA for prophylaxis of organ rejection

Even partially matched bone marrow transplants can eliminate sickle cell disease in some patients

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

Friendly bacteria: do we really need to eat probiotic yogurts?

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

HemoSep device significantly reduces need for blood transfusions during major surgeries

Diabetes Research Institute to receive JDRF-HCT grant for islet encapsulation study

FDA requests Biovest to conduct second Phase III trial of BV301 for NHL

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Schizophrenia may be linked to immune function

Rituximab also benefits patients with kidney disorder

Sirolimus has anti-skin cancer effect in kidney transplant patients

Pneumococcal revaccination needed in kidney transplant patients

Thrombopoietin mimetic offers aplastic anemia hope

UCLA Heart Transplant Program performs 2,000th heart transplant surgery

Scientists reverse diabetes in mice using stem cells

REG3A molecule may lead to new treatments for psoriasis, wound-healing

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News